Focal Segmental Glomerulosclerosis (FSGS)

RSS | Login | Register

Focal Segmental Glomerulosclerosis (FSGS)

Steroids May Harm Athletes' Kidneys

John Schieszer March 02, 2010

Serious renal damage is a possible consequence of long-term abuse of anabolic steroids, data show .

Mycophenolate Mofetil Works As Well As Standard Therapy

Jody A. Charnow July 22, 2008

Six months of mycophenolate mofetil (MMF) treatment is as effective in the short term as conventional therapy for primary treatment of membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS), a pilot study in India found.

MMF Similar to Conventional Therapies for MN, FSGS

Jody A. Charnow January 01, 2008

A six-month course of treatment with mycophenolate mofetil (MMF) is as effective as conventional therapies for treating membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS), according to a pilot study conducted in India.

Diagnosing, Treating FSGS: An Update

By Gerald B. Appel, MD, and Alice Sue Appel, PhD March 01, 2007

Focal segmental glomerulosclerosis (FSGS) is not a single disease but a histologic pattern of renal damage that initially affects the glomerulus and its tubulointerstitium.

Study Reveals Epidemiology of Glomerulopathies in Brazil

January 01, 2007

Five-year data gathered by the Paulista Registry of Glomerulopathies in São Paulo, Brazil, shows that focal and segmental glomerulosclerosis is the most common primary glomerular disease, followed by membranous nephropathy and IgA nephropathy.

Our exclusive coverage of Kidney Week 2011 in Philadelphia includes interviews, videos and noteworthy clinical reports.

Sections: Anemia | Transplantation
Secondary Hyperparathyroidism | General News
More: Videos